News & Updates

Cetuximab plus chemoradiotherapy feasible in women with cervical carcinoma

16 Jul 2022

Treatment with cetuximab plus cisplatin 30 mg/m2 and radiotherapy appears safe and well tolerated in women with cervical carcinoma, a study has shown. In addition, fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) has exhibited early evidence of response to neoadjuvant cetuximab.

Cetuximab plus chemoradiotherapy feasible in women with cervical carcinoma

16 Jul 2022

Upfront ASCT + RVd improves PFS in NDMM

16 Jul 2022 by

Upfront autologous stem cell transplantation (ASCT) plus lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), results of the phase III DETERMINATION trial showed.

Upfront ASCT + RVd improves PFS in NDMM

16 Jul 2022

Concomitant diltiazem use with DOACs pose increased bleeding risk in AF

16 Jul 2022

Taking diltiazem and direct oral anticoagulants (DOACs) together appears to contribute to increased bleeding risk in patients with atrial fibrillation (AF), regardless of the presence of chronic kidney disease, as shown in a study.

Concomitant diltiazem use with DOACs pose increased bleeding risk in AF

16 Jul 2022

Medication disrupts human gut microbiome

16 Jul 2022

Exposure to single or multiple drugs can have extensive disruptive effects on the human gut microbiome, a new study has found.

Medication disrupts human gut microbiome

16 Jul 2022

Second-line axi-cel improves EFS in elderly patients with R/R LBCL

16 Jul 2022 by

Second-line treatment with the CAR* T-cell therapy axicabtagene ciloleucel (axi-cel) led to significantly longer event-free survival (EFS) in patients aged ≥65 years with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) compared with standard of care (SoC), according to a preplanned subgroup analysis of the ZUMA-7** trial presented at EHA 2022.

Second-line axi-cel improves EFS in elderly patients with R/R LBCL

16 Jul 2022

Meta-analysis favours citalopram in poststroke recovery

15 Jul 2022 by

Selective serotonin reuptake inhibitors (SSRIs) can prevent and treat depression following stroke, in addition to improving anxiety, dependence, motor function, and cognitive function—benefits that are only reproducible with citalopram but not fluoxetine, according to a meta-analysis said to be the most up to date.

Meta-analysis favours citalopram in poststroke recovery

15 Jul 2022

GI practitioners cease PPI use in patients due to concerns of side effects

15 Jul 2022

Discontinuation of proton pump inhibitor (PPI) use remains prevalent, even within a group of mostly academic gastroenterology (GI) practitioners, despite evidence suggesting the safety of long-term PPI use without routine monitoring, a study has shown.

GI practitioners cease PPI use in patients due to concerns of side effects

15 Jul 2022

Concomitant azole use may influence bleeding risk in AF patients on NOACs

15 Jul 2022 by

In a study evaluating azole use in patients with atrial fibrillation (AF) on non-vitamin K antagonist oral anticoagulants (NOACs), systemic exposure to the antifungal agent fluconazole was associated with an elevated risk of bleeding, particularly among those on apixaban. Conversely, no association was seen between NOACs and topical azoles*.